Cambridge Healthtech Institute’s 10th International
Leaders in Biobanking Congress
Innovations to Maintain Integrity and Maximize Investment in Biospecimens
October 14-16, 2018
Today, biospecimen collections are used by multiple research groups for various aims, from basic research through clinical trials. Useful biosamples must be collected to maintain their molecular integrity for specific (or unknown) downstream analysis.
Thus, during research, biobanks are key infrastructures because at one time or another, these biospecimens have been stored in a biobank. Cambridge Healthtech Institute’s Tenth International Leaders in Biobanking Congress addresses
innovations in biospecimen science and infrastructure to support expanding applications. Maintaining the integrity of biospecimens allows biomedical and biopharmaceutical researchers, regulators, biorepository managers, and practitioners to investigate
the best strategies for effective use of biospecimens within today’s cutting-edge biomedical research.
Samples to Biomarkers – Software Tools Supporting Biomarker Discovery
Diane Leong, PhD, Director, Biobanking and Sample Management, Biomarker Sciences, Gilead Sciences
Transforming Biobanking: From Precision Diagnostics and Big Data Analytics to Tailored Drug Development
Michael Roehrl, MD, PhD, Director, Precision Pathology Biobanking Center, Memorial Sloan Kettering Cancer Center
Metal-Organic Frameworks as Protective Coating for Biospecimen Preservation
Srikanth Singamaneni, PhD, Associate Professor, Mechanical Engineering and Materials Science, Washington University in St. Louis
PBMCs: The Good, the Bad, and the Ugly, and Why You Should Store Them Anyway
Robyn Osborne, MS, Manager, Substrate Service Core & Research Support, Department of Surgery, Duke University Medical Center
Preparing Research Samples for Future Use
Andrew Brooks, PhD, COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University
Development of Tissue Print Technologies for Biopsy-Based Molecular Biomarker Studies
Sandra Gaston, PhD, Director, Molecular Biomarker Research Laboratory, Department of Pathology and Laboratory Medicine, Tufts Medical Center
Revisions to the Common Rule – What You Need to Know
Abby Statler, MPH, MA, CCRP, Research Regulatory QA Coordinator, Taussig Cancer Institute, Cleveland Clinic
Managing Change in a Biorepository: Challenges of Moving an Active Biorepository
Shana Lamers, MSc, Laboratory Manager, Clinical Research Laboratory and Biobank, Hamilton Health Sciences
Professionalizing the MRC/UVRI and LSHTM Research Unit Biorepository to International ISBER Standards
Sureyah Nassimbwa, Head, Biorepository, MRC/UVRI Biorepository, Uganda
The Cancer Moonshot Biobank
Helen Moore, PhD, Branch Chief, Biorepositories and Biospecimen Research Branch, National Cancer Institute, NIH
Biobanking for Interdisciplinary Clinical Research and Translational Programs: An Integrated and Innovative Operational Model
Zuanel Diaz, PhD, Director, Protocol Support Laboratory and Biospecimen Repository Facility, Miami Cancer Institute, Baptist Health South Florida
CASE STUDY CO-PRESENTATION: A Gift for New Sight
Kayla Gray, CCRP, Innovations Operations Supervisor, Eversight
Zala Luznik, MD, PhD, Postdoctoral Fellow, Schepens Eye Research Institute, Massachusetts Eye and Ear
For more details on the conference, please contact:
Mary Ann Brown
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: (+1) 781-972-5497
Email: mabrown@healthtech.com
For partnering and sponsorship information, please contact:
Katelin Fitzgerald
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5458
Email: kfitzgerald@healthtech.com